Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

1.5K
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.5K
Cholinergic Neurons: Neurotransmission01:23

Cholinergic Neurons: Neurotransmission

5.4K
Cholinergic neurotransmission involves the synthesis and the release of acetylcholine (ACh) in order to transmit nerve impulses across the synapse. The process begins with the synthesis of acetyl CoA, a precursor for ACh, from ATP, acetate, and coenzyme A in the mitochondria. Choline, another vital precursor, is transported inside the neuron through choline transporters, including high-affinity choline transporter CHT1, low-affinity choline transporter CTL1, and lower-affinity choline...
5.4K
Cholinergic Receptors: Muscarinic01:25

Cholinergic Receptors: Muscarinic

5.2K
The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine. 
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
5.2K
Cholinergic Receptors: Nicotinic01:15

Cholinergic Receptors: Nicotinic

5.7K
Nicotinic receptors are ligand-gated ion channels that are activated by acetylcholine and nicotine. Upon activation, they cause a rapid increase in the permeability of cells to K+, Na+, and Ca2+, followed by depolarization and excitation. They are in the autonomic ganglia, skeletal neuromuscular junction, CNS, and adrenal medulla.
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
5.7K
Cholinergic Antagonists: Pharmacokinetics01:24

Cholinergic Antagonists: Pharmacokinetics

981
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations,  while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
981
Cholinergic Antagonists: Pharmacological Actions01:28

Cholinergic Antagonists: Pharmacological Actions

1.8K
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Morphological and functional alterations in glycerol preserved rat aortic allografts.

The International journal of artificial organs·2005
Same author

Vasopressin-induced facilitation of adrenergic responses in the rat mesenteric artery is V1-receptor dependent.

Autonomic & autacoid pharmacology·2003
Same author

Pharmacological modulation of ureteral peristalsis in a chronically instrumented conscious pig model. I: Effect of cholinergic stimulation and inhibition.

The Journal of urology·2003
Same author

In vitro function of porcine carotid arteries preserved in UW, HTK and Celsior solutions.

Fundamental & clinical pharmacology·2003
Same author

The effects of hypochlorite-induced oxidative stress on presynaptic M2-receptors at sympathetic nerve endings in the rat tail artery.

Autonomic & autacoid pharmacology·2003
Same author

Characterisation of a modified approach to the study of sympathetic neurotransmission and its presynaptic modulation in the isolated rabbit thoracic aorta.

Journal of pharmacological and toxicological methods·2002

Related Experiment Video

Updated: Feb 7, 2026

The Application of 1% Methylene Blue Dye As a Single Technique in Breast Cancer Sentinel Node Biopsy
07:51

The Application of 1% Methylene Blue Dye As a Single Technique in Breast Cancer Sentinel Node Biopsy

Published on: June 1, 2019

21.4K

The interaction between methylene blue and the cholinergic system

M Pfaffendorf1, T A Bruning, H D Batnik

  • 1Department of Pharmacology, University of Amsterdam, The Netherlands.

British Journal of Pharmacology
|September 23, 1997
PubMed
Summary

Methylene blue (MB) inhibits cholinesterases and muscarinic receptors. This interaction challenges its use in studying the L-arginine-NO pathway, especially with muscarinic receptor involvement.

More Related Videos

Assessing Urinary Tract Junction Obstruction Defects by Methylene Blue Dye Injection
06:05

Assessing Urinary Tract Junction Obstruction Defects by Methylene Blue Dye Injection

Published on: October 12, 2017

16.2K
Exfoliation of Egyptian Blue and Han Blue, Two Alkali Earth Copper Silicate-based Pigments
12:04

Exfoliation of Egyptian Blue and Han Blue, Two Alkali Earth Copper Silicate-based Pigments

Published on: April 24, 2014

16.5K

Related Experiment Videos

Last Updated: Feb 7, 2026

The Application of 1% Methylene Blue Dye As a Single Technique in Breast Cancer Sentinel Node Biopsy
07:51

The Application of 1% Methylene Blue Dye As a Single Technique in Breast Cancer Sentinel Node Biopsy

Published on: June 1, 2019

21.4K
Assessing Urinary Tract Junction Obstruction Defects by Methylene Blue Dye Injection
06:05

Assessing Urinary Tract Junction Obstruction Defects by Methylene Blue Dye Injection

Published on: October 12, 2017

16.2K
Exfoliation of Egyptian Blue and Han Blue, Two Alkali Earth Copper Silicate-based Pigments
12:04

Exfoliation of Egyptian Blue and Han Blue, Two Alkali Earth Copper Silicate-based Pigments

Published on: April 24, 2014

16.5K

Area of Science:

  • Biochemistry
  • Pharmacology

Background:

  • Methylene blue (MB) is used in endothelial system research.
  • Its interaction with the cholinergic system is not fully understood.

Purpose of the Study:

  • To investigate the inhibitory effects of methylene blue (MB) on cholinesterases.
  • To assess MB's impact on [3H]-N-methylscopolamine ([3H]-NMS) binding to muscarinic receptors.

Main Methods:

  • Enzymatic assays determined MB's effect on human plasma and purified cholinesterases.
  • Radioligand binding assays quantified MB's inhibition of [3H]-NMS binding to rat cardiac tissue.

Main Results:

  • MB demonstrated concentration-dependent inhibition of esterase activity with varying IC50 values.
  • MB completely inhibited cholinesterase activity in human plasma and pseudocholinesterase.
  • MB potently inhibited [3H]-NMS binding to muscarinic receptors with a Ki of 0.58 ± 0.02 μmol/L.

Conclusions:

  • Methylene blue acts as a cholinesterase inhibitor with significant affinity for muscarinic binding sites.
  • These dual actions suggest MB may not be suitable for investigating the L-arginine-NO pathway, particularly when muscarinic receptors are involved.